TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07539415: A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers

Sponsor: Daewoong Pharmaceutical Co. LTD. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 72 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07539415 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07539415 Rescue Dossier →